Criminal Prosecution of Alpharma Inc.
In March 2010, American pharmaceutical manufacturer Alpharma Inc. paid $42.5 million to resolve FCA allegations in connection with the marketing of the morphine-based drug Kadian. The settlement resolves allegations that, between January 1, 2000 and December 29, 2008, Alpharma paid health care providers to induce them to promote or prescribe Kadian, and made misrepresentations about the safety and efficacy of the drug, which is used to treat chronic moderate to severe pain.
Source: HHS Health Care Fraud and Abuse Control Program, Annual Report for FY 2010
This article was posted on July 15, 2012.